Flunajung 150 mg (Fluconazole)

Adult dosage

The route of administration should be determined according to the patient's clinical condition. Oral preparations are rapidly and almost completely absorbed; therefore, the doses of oral preparations (tablets, capsules, dry syrup) and injections are the same. ○ Adults 1. Vaginal candidiasis: Administer a single oral dose of fluconazole 150 mg. 2. Systemic candidiasis, including candidemia, disseminated candidiasis, and other invasive Candida infections (peritoneal, endocardial, pulmonary, urinary tract, etc.): Usually administer 400 mg once on the first day, followed by 200 mg once daily from the next day; the dose may be increased to 400 mg once daily according to the patient's response. The duration of administration should be determined according to clinical response and medical judgment. 3. Cryptococcal meningitis and cryptococcosis at other sites: Usually administer 400 mg once on the first day, followed by 200-400 mg once daily from the next day. The duration of treatment is determined by clinical and mycological response, but treatment should usually continue for at least 6 ~ 8 weeks. 4. To prevent recurrence of cryptococcal meningitis in patients with AIDS, administer 200 mg once daily indefinitely after the patient has completed all initial treatment. 5. Prevention of fungal infections in immunocompromised patients at risk of fungal infection due to neutropenia caused by cytotoxic chemotherapy, radiation therapy, or bone marrow transplantation: Administer 50-400 mg once daily according to the patient's risk of fungal infection. A dose of 400 mg once daily is recommended for patients at very high risk of systemic fungal infection, such as those with severe or prolonged neutropenia following bone marrow transplantation. In these patients, administer 400 mg starting 5-6 days before the anticipated onset of neutropenia, and continue 400 mg for 1 week after the neutrophil count has increased to 1,000 cells/mm3 or more. 6. For onychomycosis, administer 150 mg once weekly until the fingernails or toenails have regrown (until new, uninfected nails have grown). New fingernails usually take 3-6 months to grow, and toenails take approximately 6-12 months; growth rates may vary from person to person and with age. Even after successful treatment with long-term administration, the fingernails or toenails may sometimes remain damaged. Dermal fungal infections, including tinea pedis, tinea corporis, tinea cruris, and cutaneous candidiasis: Usually administer 50 mg once daily or 150 mg once weekly for 2-4 weeks. However, tinea pedis may require treatment for 6 weeks depending on the course of the infection. For pityriasis versicolor, administer 50 mg once daily for 2-4 weeks. ○ Elderly patients If renal function is normal, the usual adult dose is administered. In patients with renal impairment (creatinine clearance 50 mL/min or less), the dose should be reduced or the dosing interval extended. ○ Patients with renal impairment This medicine is excreted mainly in the urine in unchanged form. No dose adjustment is necessary for a single dose. If multiple doses are required, administer the usual dose only on the first day and adjust the dose from the following day as described below. Creatinine clearance (mL/min) / Recommended dose > 50: 100 % of the usual dose ≤50 (not on dialysis): 50% of the usual dose Patients on hemodialysis: 100% of the usual dose after each hemodialysis session Patients on hemodialysis should receive 100% of the usual dose after each hemodialysis session. On days when dialysis is not performed, administer a reduced dose according to creatinine clearance.

This medication should not be used in certain patients. For instance, individuals who are allergic to this drug or other similar medications, or who are pregnant or breastfeeding, should not take it. Furthermore, concomitant use with certain other medications can lead to serious side effects; therefore, patients taking such medications should not use this drug. For example, it may be dangerous when combined with medications that affect the heart or certain antibiotics and antihistamines. This medication contains lactose, so patients with lactose intolerance or related genetic disorders should not take it. Special caution is required for patients with compromised kidney or liver function, those with heart conditions, or those with electrolyte imbalances. Regular liver function tests are important as liver function may deteriorate. This medication is likely to interact with other drugs; therefore, if there are any concomitant medications, it is essential to consult a doctor or pharmacist. Particularly, caution is needed when combining it with anticoagulants, some antidepressants, antiepileptics, immunosuppressants, and analgesics. While taking this drug, serious skin reactions or liver toxicity may rarely occur. Thus, if symptoms such as rash, itching, or jaundice appear, it's important to inform medical professionals immediately. Women who are pregnant or potentially pregnant should consult a doctor before taking this medication and should use an effective contraceptive method during treatment. This medication can also be transmitted through breast milk, so it is advisable not to use it while breastfeeding. The safety of this medication in children, especially infants under 6 months old, has not been established, thus it should only be used when absolutely necessary. There may be dizziness or seizures while driving or operating machinery, so caution is advised. In case of overdose, hallucinations or abnormal behavior may occur, and appropriate treatment should be sought at a hospital if needed. This medication is primarily excreted via urine, so increasing urine volume can facilitate drug excretion.

Agranulocytosis, leukopenia, neutropenia, thrombocytopenia, anaphylaxis, angioedema, hypertriglyceridemia, hypercholesterolemia, hypokalemia, insomnia, drowsiness, headache, seizure, dizziness, paresthesia, taste disturbance, tremor, vertigo, Torsades de pointes, QT prolongation, abdominal pain, diarrhea, nausea, vomiting, dyspepsia, bloating, dry mouth, increased ALT, increased AST, increased serum alkaline phosphatase, cholestasis, jaundice, increased bilirubin, hepatotoxicity, liver failure, hepatocyte necrosis, hepatitis, hepatocyte injury, rash, itching, urticaria, increased sweating, drug rash, toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, facial edema, hair loss, drug reaction with eosinophilia and systemic symptoms, myalgia, fatigue, malaise, asthenia, fever, adrenal insufficiency, hallucinations, paranoid behavior

This medication should be stored in a tightly closed container to prevent air or moisture from entering. This will help maintain the drug's efficacy for a longer time.

Appearance

Pink rectangular tablet

Package unit

Company packaging unit